Aurobindo Pharma Limited — JV/Acquisition, 01-01-2026: Acquisition

Aurobindo Pharma, via its subsidiary Auro Pharma, is acquiring the non-oncology prescription formulations business of Khandelwal Labs for ₹325 Cr. This strategic move significantly strengthens Aurobindo's domestic market presence, adding 23 brands in pain management and anti-infectives, complementing its existing portfolio. The acquired business generated a turnover of ₹113.5 Cr with ₹29 Cr EBITDA in FY2024-25, bringing 470 field force personnel and an established distribution network. This enhances market reach and broadens product offerings in key therapeutic areas.